These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30151275)

  • 1. Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline
    Palacio S; Pollack T; Silva-Smith R; Sussman DA; Hosein PJ
    J Gastrointest Oncol; 2018 Aug; 9(4):E19-E22. PubMed ID: 30151275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
    Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M
    Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline
    Pimenta JR; Ueda SKN; Peixoto RD
    Case Rep Oncol; 2020; 13(2):904-910. PubMed ID: 32884538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    Golan T; Barenboim A; Lahat G; Nachmany I; Goykhman Y; Shacham-Shmueli E; Halpern N; Brazowski E; Geva R; Wolf I; Goldes Y; Ben-Haim M; Klausner JM; Lubezky N
    Ann Surg Oncol; 2020 Oct; 27(10):3963-3970. PubMed ID: 32314163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.
    Palacio S; McMurry HS; Ali R; Donenberg T; Silva-Smith R; Wideroff G; Sussman DA; Rocha Lima CMS; Hosein PJ
    J Gastrointest Oncol; 2019 Dec; 10(6):1133-1139. PubMed ID: 31949930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review.
    Asiri MS; Dabaliz A; Almutairi M; Almahbub A; Alharbi M; Almeman S; AlShieban S; Alotaibi T; Algarni M
    Cureus; 2023 Aug; 15(8):e43261. PubMed ID: 37692681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients.
    Park JH; Jo JH; Jang SI; Chung MJ; Park JY; Bang S; Park SW; Song SY; Lee HS; Cho JH
    Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.
    Kubo T; Muramatsu J; Arihara Y; Murota A; Ishikawa K; Yoshida M; Nagashima H; Tamura F; Ikeda Y; Usami M; Ono M; Nakamura H; Watanabe D; Shibata T; Kasahara K; Sakurai A; Takada K
    Jpn J Clin Oncol; 2024 Jan; 54(1):47-53. PubMed ID: 37791389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
    Conroy T; Hammel P; Hebbar M; Ben Abdelghani M; Wei AC; Raoul JL; Choné L; Francois E; Artru P; Biagi JJ; Lecomte T; Assenat E; Faroux R; Ychou M; Volet J; Sauvanet A; Breysacher G; Di Fiore F; Cripps C; Kavan P; Texereau P; Bouhier-Leporrier K; Khemissa-Akouz F; Legoux JL; Juzyna B; Gourgou S; O'Callaghan CJ; Jouffroy-Zeller C; Rat P; Malka D; Castan F; Bachet JB;
    N Engl J Med; 2018 Dec; 379(25):2395-2406. PubMed ID: 30575490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.
    Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH
    Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
    Shindo K; Yu J; Suenaga M; Fesharakizadeh S; Cho C; Macgregor-Das A; Siddiqui A; Witmer PD; Tamura K; Song TJ; Navarro Almario JA; Brant A; Borges M; Ford M; Barkley T; He J; Weiss MJ; Wolfgang CL; Roberts NJ; Hruban RH; Klein AP; Goggins M
    J Clin Oncol; 2017 Oct; 35(30):3382-3390. PubMed ID: 28767289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
    Conroy T; Gavoille C; Samalin E; Ychou M; Ducreux M
    Curr Oncol Rep; 2013 Apr; 15(2):182-9. PubMed ID: 23341367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
    Okada K; Uemura K; Okamoto W; Sumiyoshi T; Shintakuya R; Otsuka H; Serikawa M; Ishii Y; Arihiro K; Takahashi S
    Clin J Gastroenterol; 2023 Apr; 16(2):283-288. PubMed ID: 36574187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
    Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
    World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.